Reminder: Oncology management program to include Blue Cross commercial members, starting Dec. 1

As we reported in the September issue of The Record, Blue Cross Blue Shield of Michigan is expanding its utilization management program for medical oncology to include all fully insured commercial members in December 2020.

Blue Cross commercial groups that are self-funded will have the option to add this program in 2021.

Providers will need to request prior authorization from AIM Specialty Health^® for certain medical oncology and supportive care medications for Blue Cross’ fully insured members.

Note: You should continue submitting prior authorization requests for two drugs for Blue Cross’ fully insured members by using the NovoLogix^® web tool. This applies to dates of service through Nov. 30, 2020. The drugs are:

• Khapzory™ — HCPCS code J0642
• Fusilev^® — HCPCS code J0641

For dates of service on or after Dec. 1, submit those requests to AIM.

Learn more about the program

The oncology management program through AIM Specialty Health is already in effect for Medicare Plus Blue℠, BCN commercial and BCN Advantage℠ members, and for UAW Retiree Medical Benefits Trust non-Medicare members.

Providers can view a list of medications managed by AIM for Blue Cross fully insured members on the Blue Cross AIM-Managed Procedures page of our ereferrals.bcbsm.com website.

You can request prior authorizations by going to the AIM ProviderPortal℠** or by calling AIM at 1-800-728-8008, beginning Nov. 16, 2020 (for services on or after Dec. 1, 2020).

For details about registering for and accessing the AIM ProviderPortal, see the Frequently Asked Questions** page of the AIM website.

For more information about our AIM medical oncology program, view these resources:

• aimproviders.com**
• Blue Cross AIM Managed Procedures page on ereferrals.bcbsm.com
• Frequently asked questions document about the oncology management program

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.